In addition to EGFR dependent resistance mechanisms, the activation of bypass pathways through the MET, AXL, IGF1R axis or the phenotypic transformation to small-cell lung cancer (SCLC) has been reported to drive resistant responses to 1G and 2G TKIs17–20. The gene discussed is IGF1R; the disease is small cell lung carcinoma.